VPI 2690B

Drug Profile

VPI 2690B

Alternative Names: VPI-2690B

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of North Carolina
  • Developer Vascular Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists; Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies

Most Recent Events

  • 01 Mar 2017 Vascular Pharmaceuticals completes a phase II trial in Diabetic nephropathies in USA and Puerto Rico (NCT02251067)
  • 09 Dec 2016 VPI 2690B is still in phase II trials for Diabetic nephropathies in USA (NCT02251067)
  • 01 Sep 2014 Phase-II clinical trials in Diabetic nephropathies in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top